ProQR Therapeutics (PRQR) Operating Leases (2017 - 2026)

ProQR Therapeutics has reported Operating Leases for 10 years, with the latest figure at $10.6 million in Q1 2026.

• Quarterly Operating Leases fell 5.98% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (down 5.98% YoY) and the FY2025 annual result came in at $11.1 million, down 6.03% from the prior year.
• Operating Leases slipped to $10.6 million in Q1 2026 per PRQR's latest filing, from $11.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $16.1 million in Q1 2022 and troughed at $10.6 million in Q1 2026.
• A 5-year average of $13.5 million and a median of $14.1 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 86630.68% in 2022, then fell 22.25% in 2025.
• Over 5 years, Operating Leases stood at $14.1 million in 2022, then gained by 5.57% to $14.9 million in 2023, then retreated by 20.51% to $11.8 million in 2024, then slipped by 6.03% to $11.1 million in 2025, then retreated by 4.44% to $10.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $10.6 million, $11.1 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.